Search research articles
Contact Us
Filters
Showing results (201-210 of 215) with videos related to
Page
of 22
Sort By:
The Journal of Clinical Investigation
|
June 16, 2022
Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype
Rebecca L Porter, Siyu Sun, Micayla N Flores, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2019
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Amit M Oza, Ursula A Matulonis, Angeles Alvarez Secord, et al.
Cancer Research
|
November 7, 2020
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
Changxin Wan, Matthew P Keany, Han Dong, et al.
Science Advances
|
July 12, 2024
CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer
Mubin Tarannum, Khanhlinh Dinh, Juliana Vergara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> Mutation
Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, et al.
The Lancet. Oncology
|
March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Molecular Cancer Research : MCR
|
August 30, 2019
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer
Elizabeth H Stover, Maria B Baco, Ofir Cohen, et al.
Nature Genetics
|
August 22, 2025
Tamoxifen induces PI3K activation in uterine cancer
Kirsten Kübler, Agostina Nardone, Shankara Anand, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 3, 2016
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Robert J Morgan, Deborah K Armstrong, Ronald D Alvarez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Ryan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 215) with videos related to
Sort By:
Page
of 22
The Journal of Clinical Investigation
|
June 16, 2022
Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype
Rebecca L Porter, Siyu Sun, Micayla N Flores, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2019
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Amit M Oza, Ursula A Matulonis, Angeles Alvarez Secord, et al.
Cancer Research
|
November 7, 2020
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
Changxin Wan, Matthew P Keany, Han Dong, et al.
Science Advances
|
July 12, 2024
CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer
Mubin Tarannum, Khanhlinh Dinh, Juliana Vergara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> Mutation
Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, et al.
The Lancet. Oncology
|
March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Molecular Cancer Research : MCR
|
August 30, 2019
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer
Elizabeth H Stover, Maria B Baco, Ofir Cohen, et al.
Nature Genetics
|
August 22, 2025
Tamoxifen induces PI3K activation in uterine cancer
Kirsten Kübler, Agostina Nardone, Shankara Anand, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 3, 2016
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Robert J Morgan, Deborah K Armstrong, Ronald D Alvarez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Ryan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Page
of 22